产品展厅收藏该商铺

您好 登录 注册

当前位置:
上海恒远生物科技有限公司>公司动态>研究表明LRG1对于在眼病中控制病理性血管治疗目标

公司动态

研究表明LRG1对于在眼病中控制病理性血管治疗目标

阅读:1476          发布时间:2013-7-23

LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling

Xiaomeng Wang, Sabu Abraham, Jenny A. G. McKenzie, Natasha Jeffs, Matthew Swire, Vineeta B. Tripathi, Ulrich F. O. Luhmann, Clemens A. K. Lange, Zhenhua Zhai, Helen M. Arthur, James W. B. Bainbridge, Stephen E. Moss & John Greenwood

Aberrant neovascularization contributes to diseases such as cancer, blindness and atherosclerosis, and is the consequence of inappropriate angiogenic signalling. Although many regulators of pathogenic angiogenesis have been identified, our understanding of this process is incomplete. Here we explore the transcriptome of retinal microvessels isolated from mouse models of retinal disease that exhibit vascular pathology, and uncover an upregulated gene, leucine-rich alpha-2-glycoprotein 1 (Lrg1), of previously unknown function. We show that in the presence of transforming growth factor-β1 (TGF-β1), LRG1 is mitogenic to endothelial cells and promotes angiogenesis. Mice lacking Lrg1 develop a mild retinal vascular phenotype but exhibit a significant reduction in pathological ocular angiogenesis. LRG1 binds directly to the TGF-β accessory receptor endoglin, which, in the presence of TGF-β1, results in promotion of the pro-angiogenic Smad1/5/8 signalling pathway. LRG1 antibody blockade inhibits this switch and attenuates angiogenesis. These studies reveal a new regulator of angiogenesis that mediates its effect by modulating TGF-β signalling.

    选择恒远生物,您将得到高质量的产品、实惠的价格、的服务、快捷的到货、稳定的货源、;
 !我们会定期推出市场活动,及时给您提供足够的市场*和产品资料!我们提供一切售前支持和售后服务!我们的http://www.rdelisa.com 可以查到大部分产品详细信息、价格(具体产品说明书可以找我们索取),它必将成为您和您客户的有力工具!

收藏该商铺

登录 后再收藏

提示

您的留言已提交成功!我们将在第一时间回复您~

对比框

产品对比 产品对比 联系电话 二维码 意见反馈 在线交流

扫一扫访问手机商铺
在线留言